Dasatinib inhibits both osteoclast activation and prostate cancer PC-3 cell-induced osteoclast formation

Cancer Biology and Therapy

Volumn 8, Issue 22, 2009, Pages 2153-2159

  Araujo, John C ^a   Poblenz, Ann ^a   Corn, Paul ^a   Parikh, Nila U ^a   Starbuck, Michael W ^a   Thompson, Jerry T ^b   Lee, Francis ^c   Logothetis, Christopher J ^a   Darnay, Bryant G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c Pharmaceutical Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; DASATINIB; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE; TNFSF11 PROTEIN, HUMAN; TNFSF11 PROTEIN, MOUSE; TUMOR PROTEIN;

ADENOCARCINOMA; ANIMAL; ARTICLE; BONE MARROW CELL; BONE TUMOR; C57BL MOUSE; CELL DIFFERENTIATION; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; MALE; METABOLISM; METASTASIS; MONOCYTE; MOUSE; OSTEOCLAST; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; BONE MARROW CELLS; BONE NEOPLASMS; CELL DIFFERENTIATION; CELL LINE, TUMOR; COLLAGEN; HUMANS; MALE; MICE; MICE, INBRED C57BL; MONOCYTES; NEOPLASM PROTEINS; OSTEOCLASTS; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RANK LIGAND; SRC-FAMILY KINASES; THIAZOLES;

EID: 77951496674     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.22.9770     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer Statistics, 2008. CA Cancer J Clin 2008; 58:71-96. (Pubitemid 351521864)
2. Loberg RD, Logothetis CJ, Keller ET, Pienta KJ. Pathogenesis and Treatment of Prostate Cancer Bone Metastases: Targeting the Lethal Phenotype. J Clin Oncol 2005; 23:8232-41. (Pubitemid 46211560)
3. Pienta KJ, Smith DC. Advances in Prostate Cancer Chemotherapy: A New Era Begins. CA Cancer J Clin 2005; 55:300-18. (Pubitemid 41377334)
4. Charhon SA, et al. Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma with special reference to osteomalacia. Cancer 1983; 51:918-24.
5. Clarke NWMJ, George NJ. Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer. Br J Urol 1992; 69:64-70.
6. Corey E, Brown LG, Kiefer JA, Quinn JE, Pitts TEM, Blair JM, Vessella RL. Osteoprotegerin in Prostate Cancer Bone Metastasis. Cancer Res 2005; 65:1710-8. (Pubitemid 40478596)
7. Fizazi K, Yang J, Peleg S, Sikes CR, Kreimann EL, Daliani D, et al. Prostate Cancer Cells-Osteoblast Interaction Shifts Expression of Growth/Survival-related Genes in Prostate Cancer and Reduces Expression of Osteoprotegerin in Osteoblasts. Clin Cancer Res 2003; 9:2587-97. (Pubitemid 36842101)
8. Percival RCUG, Harris S, Yates AJ, Williams JL, Beneton M, Kanis JA. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol 1987;13:41-9. (Pubitemid 17040425)
9. Urwin GHPR, Harris S, Beneton MN, Williams JL, Kanis JA. Generalised increase in bone resorption in carcinoma of the prostate. Br J Urol 1985; 57:721-3. (Pubitemid 16211558)
10. Yonou H, Kanomata N, Goya M, Kamijo T, Yokose T, Hasebe T, et al. Osteoprotegerin/Osteoclastogenesis Inhibitory Factor Decreases Human Prostate Cancer Burden in Human Adult Bone Implanted into Nonobese Diabetic/Severe Combined Immunodeficient Mice. Cancer Res 2003; 63:2096-102. (Pubitemid 36538612)
11. Zhang J, Qi Y, Lin DL, Smith P, Strayhorn C, Mizokami A, et al. Osteoprotegerin inhibits prostte cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001; 107:1235.
12. Schneider A, Kalikin LM, Mattos AC, Keller ET, Allen MJ, Pienta KJ, McCauley LK. Bone Turnover Mediates Preferential Localization of Prostate Cancer in the Skeleton. Endocrinology 2005; 146:1727-36. (Pubitemid 40396881)
13. Michaelson MD, Marujo RM, Smith MR. Contribution of Androgen Deprivation Therapy to Elevated Osteoclast Activity in Men with Metastatic Prostate Cancer. Clin Cancer Res 2004; 10:2705-8. (Pubitemid 38509145)
14. Boyce BFYT, Lowe C, Soriano P, Mundy GR. Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest 1992; 90:1622-7.
15. Lakkakorpi PTVH. Kinetics of the osteoclast cytoskeleton during the resorption cycle in vitro. J Bone Miner Res 1991; 6:817-26.
16. Lakkakorpi PT, Bett AJ, Lipfert L, Rodan GA, Duong LT. PYK2 Autophosphorylation, but Not Kinase Activity, Is Necessary for Adhesion-induced Association with c-Src, Osteoclast Spreading and Bone Resorption. J Biol Chem 2003; 278:11502-12. (Pubitemid 36792711)
17. Teti A, Marchisio PC, Zallone AZ. Clear zone in osteoclast function: role of podosomes in regulation of bone-resorbing activity. Am J Physiol Cell Physiol 1991; 261:1-7.
18. Wang Q, Xie Y, Du Q-S, Wu X-J, Feng X, Mei L, et al. Regulation of the formation of osteoclastic actin rings by proline-rich tyrosine kinase 2 interacting with gelsolin. J Cell Biol 2003; 160:565-75. (Pubitemid 36254394)
19. Duong LT, Lakkakorpi PT, Nakamura I, Machwate M, Nagy RM, Rodan GA. 19 PYK2 in Osteoclasts is an Adhesion Kinase, Localized in the Sealing Zone, Activated by Ligation of alpha(v)beta3 integrin, and Phosphorylated by Src Kinase. J Clin Invest 1998; 102:881.
20. Lowe C, Yoneda T, Boyce BF, Chen H, Mundy GR, Soriano P. Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts. Proceedings of the National Academy of Sciences of the United States of America 1993; 90:4485-9. (Pubitemid 23148929)
21. Schwartzberg PL, Xing L, Hoffmann O, Lowell CA, Garrett L, Boyce BF, Varmus HE. Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src-/- mutant mice. Genes Dev 1997; 11:2835-44. (Pubitemid 27481684)
22. Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991; 64:693-702. (Pubitemid 121001157)
23. Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proceedings of the National Academy of Sciences of the United States of America 2005; 102:3395-400. (Pubitemid 40328056)
24. Sawyers CL, Shah NP, Kantarjian HM, Donato N, Nicoll J, Bai SA, et al. Hematologic and Cytogenetic Responses in Imatinib-Resistant Chronic Phase Chronic Myeloid Leukemia Patients Treated with the Dual SRC/ABL Kinase Inhibitor BMS-354825: Results from a Phase I Dose Escalation Study. ASH Annual Meeting Abstracts 2004; 104:1.
25. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor. Science 2004; 305:399-401. (Pubitemid 38938156)
26. Tokarski JS, Newitt J, Lee FY, Lombardo L, Borzilleri R, Kish K, et al. The Crystal Structure of Abl Kinase with BMS-354825, a Dual SRC/ABL Kinase Inhibitor. ASH Annual Meeting Abstracts 2004; 104:553.
27. Nam S, Kim D, Cheng JQ, Zhang S, Lee J-H, Buettner R, et al. Action of the Src Family Kinase Inhibitor, Dasatinib (BMS-354825), on Human Prostate Cancer Cells. Cancer Res 2005; 65:9185-9. (Pubitemid 41507982)
28. Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY, et al. Targeting Src Family Kinases Inhibits Growth and Lymph Node Metastases of Prostate Cancer in an Orthotopic Nude Mouse Model. Cancer Res 2008; 68:3323-33.
29. Sanjay A, Houghton A, Neff L, DiDomenico E, Bardelay C, Antoine E, et al. Cbl Associates with Pyk2 and Src to Regulate Src Kinase Activity, {{alpha}} v{beta}3 Integrin-mediated Signaling, Cell Adhesion and Osteoclast Motility. J Cell Biol 2001; 152:181-96.